TEVA · XBRL financial data

Teva Pharmaceutical Industries financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (TEVA's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Revenue	—	—	—	—	—	—	—	—	1,500	—	—	—
Revenue from contracts with customers	4,457*	3,819	4,164	4,332	4,229*	3,891	4,176	4,480	4,711*	3,982	4,142	4,395
Cost of goods and services sold	2,041*	2,048	2,140	2,183	2,109*	2,014	2,074	2,176	2,056*	2,011	1,989	1,955
Gross profit	2,415*	1,771	2,024	2,148	2,121*	1,877	2,102	2,304	—	1,972	2,153	2,440
General and administrative	292*	278	283	298	302*	297	305	317	367*	304	317	298
Other operating income (expense)	6*	(1)	2	21	(8)*	(5)	(4)	(7)	(3)*	9	19	68
Operating income (loss)	722*	(218)	(5)	(51)	(29)*	519	455	882	300*	652	(231)	714
Interest expense	year only	—	—	—	year only	—	—	—	year only	—	—	—
Income tax expense (benefit)	41*	(52)	630	69	28*	74	(78)	214	(390)*	67	121	66
Net income (loss)	429*	(139)	(846)	(437)	(217)*	214	282	433	480*	369	(576)	233
Earnings per share, basic USD per share	0.38*	(0.12)	(0.75)	(0.39)	(0.19)*	0.19	0.25	0.38	0.42*	0.32	(0.49)	0.20
Earnings per share, diluted USD per share	0.39*	(0.12)	(0.75)	(0.39)	(0.19)*	0.18	0.24	0.37	0.41*	0.31	(0.49)	0.20
Weighted average shares, basic millions of shares	1,120*	1,123	1,133	1,133	1,135*	1,138	1,147	1,147	1,148*	1,156	1,165	1,166
Weighted average shares, diluted millions of shares	1,106*	1,123	1,133	1,133	1,135*	1,159	1,161	1,164	1,168*	1,179	1,165	1,183

Balance sheet

CSV

Fiscal quarters (TEVA's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Cash and cash equivalents	3,226	2,991	2,258	3,319	3,300	1,697	2,161	2,203	3,556	3,741	3,655	4,085
Accounts receivable	3,408	3,456	3,766	3,462	3,059	3,384	3,564	3,810	3,709	3,393	3,493	3,837
Inventory	4,021	3,949	3,927	3,959	3,007	3,247	3,497	3,323	3,179	3,176	3,221	3,173
Total current assets	12,485	12,297	11,632	12,314	12,552	11,528	12,620	12,736	13,946	13,710	13,760	14,602
Property and equipment, net	5,750	5,618	5,573	5,672	4,581	4,631	4,810	4,820	4,080	3,998	3,928	3,747
Right-of-use asset	397	364	358	364	367	363	358	342	345	335	333	321
Goodwill	17,177	17,007	16,488	16,124	15,147	15,477	15,949	15,945	16,000	15,822	15,839	15,742
Total assets	43,479	42,773	41,338	41,758	39,326	38,415	40,131	39,856	40,748	40,040	39,857	40,042
Accounts payable	108	—	—	—	158	—	—	—	225	—	—	—
Current portion of long-term debt	1,649	3,037	2,071	2,557	1,758	398	441	1	1,798	2,600	4,500	4,038
Total current liabilities	12,247	13,792	13,037	13,797	12,796	11,157	11,861	11,491	13,456	13,532	15,646	15,425
Lease liability, non-current	320	294	281	295	296	288	296	283	288	280	282	266
Total liabilities	35,353	35,230	34,774	35,375	33,606	32,146	33,297	32,602	32,834	31,809	32,100	32,057
Accumulated deficit	(13,534)	(13,673)	(14,519)	(14,956)	(15,173)	(14,958)	(14,676)	(14,243)	(13,762)	(13,394)	(13,969)	(13,736)
Total stockholders' equity	7,506	7,278	6,359	6,065	5,373	6,262	6,827	7,250	7,910	8,228	7,753	7,979
Total liabilities and equity	43,479	42,773	41,338	41,758	39,326	38,415	40,131	39,856	40,748	40,040	39,857	40,042
Common shares outstanding (cover page) millions of shares	1,121	1,133	1,133	1,133	1,134	1,147	1,147	1,147	1,150	1,164	1,165	1,167

Cash flows

CSV

Fiscal quarters (TEVA's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Net income (loss)	429*	(139)	(846)	(437)	(217)*	214	282	433	480*	369	(576)	233
Stock-based compensation	28*	28	32	29	34*	34	38	34	51*	43	40	38
Depreciation and amortization	—	—	—	—	—	—	—	249	—	—	—	245
Net cash from operating activities	1,184*	(124)	103	693	575*	(105)	227	369	1,158*	(40)	411	241
Net cash from investing activities	301*	144	178	268	202*	201	236	135	165*	229	(491)	210
Repayments of long-term debt	0*	0	956	0	685*	1,368	2,300	444	0*	—	—	—
Net cash from financing activities	(576)*	(151)	(966)	0	(674)*	(1,744)	6	(453)	40*	13	(1)	6
Net change in cash	977*	(236)	(733)	1,061	(18)*	(1,603)	464	42	1,353*	185	(86)	430

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Teva Pharmaceutical Industries	4,085	4,395	241	1.2B	—	Q3 FY26 10-QSep 30, 2026
Biogen	1,304	2,804	641*	147.8M	—	Q3 FY26 10-QSep 30, 2026
INSMED	397	524	(36)*	219.4M	—	Q3 FY26 10-QSep 30, 2026
BeOne Medicines	5,098	1,705	463*	1.5B	—	Q2 FY26 10-QJun 30, 2026
United Therapeutics	1,803	783	314*	42.9M	—	Q2 FY26 10-QJun 30, 2026
Roivant Sciences	1,248	1.4	(271)	722.3M	14.2 quarters	Q1 FY26 10-QJun 30, 2026
Neurocrine Biosciences	642	1,123	395*	101.2M	—	Q3 FY26 10-QSep 30, 2026
Exelixis	305	659	280*	244.0M	—	Q3 FY26 10-QOct 2, 2026
BIO-TECHNE	265	321*	95*	156.8M	—	Q4 FY26 10-KJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.